

# miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6

QIANG WEN<sup>1</sup>, JIE ZHAO<sup>1</sup>, LIN BAI<sup>1</sup>, TONGTONG WANG<sup>1</sup>, HAISHAN ZHANG<sup>2\*</sup> and QINGJIE MA<sup>1\*</sup>

Departments of <sup>1</sup>Nuclear Medicine and <sup>2</sup>Surgery, China-Japan Union Hospital of Jilin University, Nanguan, Changchun, Jilin 13033, P.R. China

Received May 11, 2015; Accepted June 26, 2015

DOI: 10.3892/or.2015.4165

**Abstract.** microRNA-126 (miR-126) has been reported to play tumor suppressor roles in various types of cancers. Although it has been reported that miR-126 expression is downregulated in papillary thyroid carcinoma (PTC), the precise role and underlying molecular mechanism of miR-126 in PTC remains unclear. Therefore, the aims of the present study were to investigate the role and potential mechanism of miR-126 in tumorigenicity of PTC *in vivo* and *in vitro*. We observed that the miR-126 expression level was significantly downregulated in PTC tissue and PTC cell lines, the aberrant expression of miR-126 was correlated with lymph node metastasis, tumor size and TNM stage. We also showed that restoration of miR-126 in PTC cells inhibited cell proliferation, colony formations, migration and invasion, promoted cell apoptosis and cell cycle arrest at G1 stage *in vitro*, as well as inhibited tumor growth and decreased tumor volume and weight *in vivo*. Furthermore, low-density lipoprotein receptor-related protein 6 (LRP6), a regulator of the Wnt/ $\beta$ -catenin signaling cascade, was identified as a crucial target gene of miR-126. Overexpression of miR-126 inhibited LRP6 expression on mRNA and protein levels, and deactivate Wnt/ $\beta$ -catenin signaling pathway. These results suggested that miR-126 functions as a tumor-suppressive miRNA by targeting LRP6 regulating Wnt/ $\beta$ -catenin signaling pathway and represents a therapeutic target for PTC.

## Introduction

Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, and its incidence has been steadily increasing in the last decades worldwide (1). The majority of patients with PTC have excellent prognosis and therapeutic response with a combination of radioiodine and levothyroxine after surgical resection (2), however, ~10% of patients present recurrence and metastasis in local/regional and distant sites within 10 years (3). It has been shown that poor prognosis was associated with certain clinical and pathological characteristics, such as, tumor size, extrathyroidal invasion, lymph node metastasis and advanced tumor-node-metastasis (TNM) stage (1,3). Therefore, further investigation into the progression of PTC initiation and pathogenesis, which contributes to the exploration of effective schemes for PTC diagnosis and therapy, is required.

MicroRNAs (miRNAs) are a class of highly conserved small (19-25 nucleotides) non-coding RNAs that regulate diverse cellular processes by binding to the 3' untranslated region (3'UTR) of target messenger RNAs (mRNAs) (4,5). It has been shown that miRNAs play crucial roles in a vast range of biological processes, including cell proliferation, angiogenesis, cell cycle, migration and migration (6). Accumulating studies have demonstrated that miRNAs function as tumor promoter or suppressor (7), and are involved in tumor development, progression and metastasis (8). Considering the modulation of miRNAs during tumorigenesis, they are currently considered as novel diagnosis biomarkers or therapy agents for tumor diagnosis and therapy.

miR-126, an important functional miRNA, has been reported to be commonly downregulated in various types of cancers (9). Growing evidence shows that miR-126 plays crucial roles in regulating cellular growth, migration, invasion and apoptosis in several types of tumors, such as hepatocellular carcinoma (10), osteosarcoma (11), non-small cell lung (12) and gastric cancer (13), cervix (14), colorectal (15) and colon cancer (16). A previous study indicated that miR-126 expression was downregulated in thyroid carcinomas (PTC and follicular carcinoma) compared to benign tumors (17). However, the clinical significance and the details roles of miR-126 in PTC remain unknown. In the present study, we examined the expression patterns of miR-126 in PTC tissue comparing to corresponding adjacent normal tissue, and

---

*Correspondence to:* Professor Haishan Zhang, Department of Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Nanguan, Changchun, Jilin 13033, P.R. China  
E-mail: zhanghaisjlu@163.com

Professor Qingjie Ma, Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Nanguan, Changchun, Jilin 13033, P.R. China  
E-mail: maqingjie1559@sina.com

\*Contributed equally

**Key words:** papillary thyroid carcinoma, miR-126, LRP6, Wnt/ $\beta$ -catenin

investigated the effect of miR-126 on PTC growth *in vitro* and *in vivo*. We identified low-density lipoprotein receptor-related protein 6 (LRP6) as a direct target of miR-126 and showed that overexpression of miR-126 in PTC cells inhibited cell proliferation, migration and invasion and suppressed tumor growth in a nude mouse model. These findings indicate that miR-126 may serve as a therapeutic target for PTC.

## Materials and methods

**Patients and specimens.** The present study was approved by the Institutional Ethics Committee of Jilin University. Written consent was obtained from all patients prior to surgery. Thirty paired thyroid papillary cancer specimens and adjacent normal thyroid papillary tissues were collected from the Department of Pathology, China-Japan Union Hospital of Jilin University (Changchun, China) between September 2012 and December 2014. The corresponding adjacent normal tissues from the same patients with PTC were obtained 3 cm beyond the boundary of PTC tissues. The samples were immediately snap-frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  until use. All samples were confirmed as thyroid papillary cancer by trained pathologists. No patients received chemotherapy or radiotherapy prior to surgery. Clinicopathological parameters including patient age, gender, tumor size, lymph node metastasis and TNM stage were collected and listed in Table I.

**Cell lines and culture.** Two human PTC cell lines, TPC-1 and K1, and human thyroid follicular epithelial cells (Nthy-ori 3-1) were obtained from the Type Culture Collection of the Chinese Academy of Sciences. All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (both from Gibco, USA), penicillin (100 U/ml; Sigma-Aldrich, St. Louis, MO, USA) and streptomycin (100  $\mu\text{g}/\text{ml}$ ) (Enpromise, Hangzhou, China) at  $37^{\circ}\text{C}$  in a humidified chamber supplemented with 5%  $\text{CO}_2$ . Cells at  $\sim 90\%$  confluence were split at 1:2 ratio every 2-3 days.

**RNA oligoribonucleotides, plasmids and transfection.** miR-126 mimic and corresponding negative control (miR-NC) were purchased from RiboBio (Guangzhou, China). The 3'-UTRs of human LRP6 (pGL3-LRP6 Wt) containing the potential binding sites of miR-126 were PCR-amplified from genomic DNA and cloned separately into the pGL3 luciferase reporter plasmid (Promega, Madison, WI, USA). Mutation in the miR-126 binding site module of LRP6 (pGL3-LRP6 Mut) was introduced using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manual instructions. Transfection was performed in TPC-1 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol.

**RNA extraction and quantitative real-time PCR (qRT-PCR).** Total RNA of cells and tissues was extracted using TRIzol (Invitrogen) according to the manufacturer's instruction. Total RNA was reversely transcribed to cDNA using the PrimeScript RT reagent kit (Takara Bio, Japan), and quantitative PCR was performed using Fast SYBR-Green master mix (Applied Biosystems, Foster City, CA, USA) under ABI 7900 sequence detection system (Life Technologies, Grand Island, NY, USA).

Table I. Association between miR-126 expression and clinicopathological features of human papillary thyroid carcinoma (PTC).

Variables	No. of cases	miR-126 expression		P-value
		Low (n%)	High (n%)	
Age (years)				>0.05
<50	12	6 (50.0)	6 (50.0)	
$\geq 50$	18	8 (44.4)	10 (55.6)	
Gender				>0.05
Male	14	6 (42.9)	8 (57.1.8)	
Female	16	8 (50.0)	8 (50.0)	
TNM stage				<0.05
I-II	18	6 (33.3)	12 (66.6)	
III-IV	12	8 (75.0)	4 (25.0)	
Tumor size (cm)				<0.01
<5	20	6 (30.0)	14 (70.0)	
$\geq 5$	10	8 (80.0)	2 (20.0)	
Lymph node metastasis				<0.01
No	21	6 (28.6)	15 (71.4)	
Yes	9	8 (88.9)	1 (11.1)	

The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control for mRNAs. The specific primers for GAPDH and LRP6 were as follows: GAPDH (sense), 5'-TCAACGACCACCTTTGTCAAGCTCA-3' and GAPDH (antisense), 5'-GCTGGTGGTCCAGGGGTCTTACT-3'; LRP6 (sense), 5'-GCTCAGAGTCCCAGTTCCAG-3' and LRP6 (antisense), 5'-TCCCTTCATACGTGGACACA-3'.

To quantify the miR-126 expression levels, the expression of small nuclear U6 was used as an internal control. The relative expression level of miR-126 and U6 was determined using mirVana qRT-PCR miRNA detection kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions under ABI 7900 sequence detection system. The specific primers for miRNA-126 and U6 were purchased from Applied Biosystems. All experiments were performed in triplicate. Relative expression levels were calculated using the  $2^{-\Delta\Delta\text{Ct}}$  method.

**Cell viability and colony formation assay.** Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, transfected cells ( $1 \times 10^4$ ) were cultured in 96-well plates and stained at the indicated time points (24, 48 and 72 h) with 100  $\mu\text{l}$  sterile MTT (0.5 mg/ml; Sigma) for 4 h at  $37^{\circ}\text{C}$ , followed by removal of the culture medium and the addition of 150  $\mu\text{l}$  dimethylsulfoxide (DMSO; Sigma-Aldrich), followed by the measurement of the absorbance at 490 nm. Three independent experiments were performed for colony formation assay, transfected cells were trypsinized and seeded into 6-well plates ( $1 \times 10^3$  cells/well). After 2 weeks, cells were

fixed with 10% formaldehyde for 15 min, stained with 1.0% crystal violet (both from Sigma) for 5 min, and then counted and photographed under a light microscope (Olympus, Tokyo, Japan). The percentage colony formation was calculated by adjusting miR-Ctrl to 100%. All experiments were performed in triplicate.

**Cell cycle and apoptosis assay.** Cell cycle and apoptosis assay were performed on TPC-1 cells 48 h after transfection. For the cell cycle, transfected cells in a culture dish were harvested by trypsinization, washed in ice-cold phosphate-buffered saline (PBS), and fixed in 80% ice-cold ethanol. Bovine pancreatic RNase (2  $\mu\text{g}/\text{ml}$ ; Sigma-Aldrich) was added to the cells and cultured for 30 min incubation at 37°C, and then incubated in propidium iodide (10  $\mu\text{g}/\text{ml}$ ; Invitrogen) at 4°C for 30 min in the dark. Propidium iodide-stained cells (>10,000 cells) were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). All experiments were performed in triplicate.

Cell apoptosis assay was performed using Annexin V/propidium iodide detection kit (KeyGene, Nanjing, China) by a FACSCalibur flow cytometer (BD Biosciences) according to the manufacturer's protocol. The apoptosis ratio was calculated using CellQuest 3.3 software (BD Biosciences).

**Wound-healing assay.** Transfected cells ( $2 \times 10^4$ ) were seeded into a 6 cm dish and cultured for 24 h at 37°C in a 5% CO<sub>2</sub> incubator. After incubation, the linear wound of cellular monolayer was created by scratching confluent cell monolayer. The monolayer of scratched cells was washed by PBS to remove debris. After incubation for 24 h at 37°C with 5% CO<sub>2</sub>, area of migration was photographed under a microscope (Olympus) for evaluation.

**In vitro invasion assay.** The invasive capacity of TPC-1 cells was assessed using the BioCoat Invasion Chamber system (BD Biosciences, San Jose, CA, USA). Twenty-four hours after transfection,  $2 \times 10^4$  transfected cells were diluted in serum-free RPMI-1640 medium and plated on the top of Matrigel invasion chambers coated with Matrigel (8- $\mu\text{m}$  pore size; BD Biosciences). A volume of 2.5 ml of RPMI-1640 medium containing 10% FBS was added to the lower compartment. The invasion assay was performed for 24 h at 37°C in a 5% CO<sub>2</sub> incubator. After incubation, non-invading cells were removed by scrubbing, and migrated cells present on the lower surface of the membrane were fixed in 70% ethanol for 30 min and stained with 2% crystal violet for 10 min on a glass slide. Cells from 10 random fields were counted under an IX51 inverted microscope (Olympus).

**Luciferase reporter assay.** TPC-1 cells ( $1 \times 10^4$ ) were seeded into a 24-well plate, when 50-70% confluent they were co-transfected with miR-126 mimic or miR-Ctrl and 100 ng plasmid pGL3-LRP6 Wt or pGL3-LRP6 Mut using Lipofectamine 2000 according to the manufacturer's protocol. Forty-eight hours after transfection, cells were collected and luciferase activity was measured using the Dual-Luciferase Reporter Assay system (Promega Corporation, Madison, WI, USA). The specific activity is expressed as the fold-change of

the experimental group vs. the miR-Ctrl group. The tests were repeated in 3 independent experiments.

**TCF/LEF transcriptional activity assay.** Reporter plasmids containing wild-type (CCTTTGATC; TOPflash) or mutated (CCTTTGGCC; FOPflash) T cell factor (TCF)/LEF DNA binding sites were purchased from Upstate Biotechnology (Lake Placid, NY, USA). TPC-1 cells ( $1 \times 10^4$ ) were seeded into a 24-well plate, at 50-70% confluence they were co-transfected with miR-126 mimic or miR-Ctrl and 100 ng wild-type/mutated type plasmid using Lipofectamine 2000 according to the manufacturer's protocol, and cultured for 48 h, then luciferase activity was measured using the dual-luciferase reporter assay system.

**Nude mouse xenograft assay.** Twenty female BALB/c mice (18-20 g, 4-5 weeks old) were purchased from the Experimental Animal Center of Changchun Biological Institute (Changchun, China), and kept under specific pathogen-free (SPF) conditions. All experimental procedures involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health. Animal protocols were approved by the Institutional Animal Care and Use Committee of Jilin University (Changchun, China).

TPC-1 cells ( $2 \times 10^6$ ) stably expressing miR-126 or miR-Ctrl, were suspended in 100  $\mu\text{l}$  PBS and then injected subcutaneously into the posterior flank of female BALB/c athymic nude mice. Tumor volumes in mice were measured with a slide caliper every week until the sacrifice. Tumor volumes were calculated according to the formula: Volume ( $\text{mm}^3$ ) =  $1/2 \times \text{width}^2 \times \text{length}$ . Five weeks after injection, mice were sacrificed and tumors tissues were resected and weighed. Total protein of tumor tissues was extracted to measure the LRP6 protein expression level by western blotting.

**Western blotting.** The cells were lysed in ice-cold RIPA buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 48 h post-transfection. The total proteins were quantitated using BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA). Total protein lysates (30  $\mu\text{g}/\text{each lane}$ ) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes (NC membranes; Invitrogen), blocked in 4% dry milk at room temperature for 1 h, and immunostained with primary antibodies at 4°C overnight using the following antibodies: anti-LRP6, anti-MMP-7, anti-CCND1, anti-c-Myc, anti-cyclin D1 and anti- $\beta$ -actin (all from Santa Cruz, Biotechnology, Inc.). The anti- $\beta$ -actin antibody (Santa Cruz, Biotechnology, Inc.) was used to normalize the protein input. After washing, membranes were incubated with corresponding secondary antibodies for 1 h at room temperature. The blots were detected, and visualized using an enhanced chemiluminescence kit (GE Healthcare) according to the manufacturer's instructions.

**Statistical analysis.** All data are expressed as mean  $\pm$  standard deviation (SD) of at least 3 independent experiments or 3 samples. The difference between groups was analyzed using a Student's t-test. Statistical comparison of more than




Figure 1. Expression of miR-126 is downregulated in PTC tissue and cell lines. (B) Real-time quantitative RT-PCR (qRT-PCR) analysis of miR-126 expression in PTC tissue (T) and their adjacent non-cancerous thyroid tissues (ANT). (B) Real-time PCR analysis of miR-126 expression in normal thyroid follicular epithelial cells Nthy-ori 3-1 and in two PTC cell lines TPC-1 and K1. The average miR-126 expression was normalized using U6 expression. \* $P < 0.05$ , \*\* $P < 0.01$ . PTC, papillary thyroid carcinoma.

two groups was performed using one-way ANOVA followed by a Tukey's post hoc test. The association between miR-126 expression and clinicopathological variables was assessed by the Chi-square tests. Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).  $P < 0.05$  was considered to indicate a statistically significant result.

## Results

**Expression of miR-126 is downregulated in PTC tissue and cell lines.** The expression of miR-126 was detected in 30 pairs of human PTC tissue and adjacent normal tissues by real-time quantitative RT-PCR (qRT-PCR). As shown in Fig. 1A, the miR-126 was markedly decreased in PTC tissues samples when compared with adjacent normal tissues ( $P < 0.01$ ). Among these 30 cases, 27 cases revealed a relative lower level in PTC, which suggested that reduction of miR-126 was a frequent event in human PTC. To investigate the clinical relevance of miR-126 in HCC, we divided the 30 patients to high miR-126 expression group ( $n = 16$ ) and low miR-126 expression group ( $n = 14$ ) using the mean value ( $0.402 \pm 0.05$ ) of relative expression levels in all 30 PTC tumors as a cut-off. It was found that the aberrant expression of miR-126 was correlated with lymph node metastasis ( $P < 0.01$ ), tumor size ( $P < 0.01$ ) and TNM stage ( $P < 0.01$ ), which are all indicators of poor prognosis (Table I). No significant association was found between the expression of miR-126 and age or gender in the PTC (Table I).

Furthermore, miR-126 expression was determined by RT-PCR in two PTC cell lines (TPC-1 and K1) and human thyroid follicular epithelial cells (Nthy-ori 3-1). Notably, miR-126 expression was downregulated in PTC cell lines compared to normal thyroid cells (Nthy-ori 3-1) (Fig. 1B). The data above suggest that miR-126 was decreased in both PTC tissues and cell lines. We selected the TPC-1 cells, which showed the lowest expression of miR-126, to conduct further experiments.

**Overexpression of miR-126 inhibits cell proliferation, colony formation, induces cell cycle and apoptosis of PTC cells.** To

explore the potential role of miR-126 in PTC cell growth, we transfected TPC-1 cells with miR-126 mimics and then performed *in vitro* cell proliferation and colony formation, cell cycle and apoptosis assays at indicated times. qRT-PCR confirmed that TPC-1 cells transfected with miR-126 mimic significantly increased miR-126 expression level compared to cells transfected with miR-Ctrl (Fig. 2A). MTT and clone formation assays showed that overexpression of miR-126 in TPC-1 cells significantly inhibited cell proliferation (Fig. 2B) and colony formation (Fig. 2C). As proliferation directly associated with cell cycle distribution, the effect of miR-126 on cell cycle progression was evaluated in TPC-1 cells. As expected, the percentage of G1 phase cells increased, and the percentage of S phase cells decreased in TPC-1 cells transfected with miR-126 mimic compared to cells transfected with miR-Ctrl (Fig. 2D). In addition, cell apoptosis was investigated in TPC-1 cells transfected with miR-126 mimic or miR-Ctrl. The result showed that overexpression of miR-126 increased cell apoptosis relative to miR-Ctrl group (Fig. 2E).

**Overexpression of miR-126 inhibits cell migration and invasion of PTC cells.** The above results showed that miR-126 downregulation was associated with lymph node metastasis in patients with PTC, therefore, to investigate whether miR-126 affect metastasis *in vitro*, migration and invasion assays were performed in TPC-1 cells transfected with miR-126 mimic or miR-Ctrl by wound healing and Transwell assays, respectively. Consistent with the clinical data, overexpression of miR-126 in TPC-1 cells significantly inhibited cell migration (Fig. 3A) and invasion (Fig. 3B). Collectively, these results suggested that miR-126 efficiently inhibits migration and invasion of PTC cells.

**LRP6 is a direct target of miR-126.** To explore the mechanism underlying the growth inhibition by miR-126 in PTC cells, we used publicly available algorithms (TargetScan6.2 and miRanda) to help identify the miR-126 targets in human PTC. The results showed that there is a miR-126 binding site in LRP6 mRNA 3'UTR (Fig. 4A). As predicted, qRT-PCR and western blotting showed that ectopic miR-126 in TPC-1 cells




Figure 2. Overexpression of miR-126 inhibits cell proliferation and colony formation and promotes cell apoptosis and cycle at G0/G1 stage in PTC cells. (A) The relative expression levels of miR-126 in TPC-1 cells were determined by qRT-PCR after transfection with miR-126 or miR-Ctrl. (B) Cell proliferation, (C) colony formation, (D) cycle and (E) apoptosis were determined in TPC-1 cells after transfection with miR-126 or miR-Ctrl. \* $P < 0.05$ , \*\* $P < 0.01$  vs. miR-Ctrl. PTC, papillary thyroid carcinoma.




Figure 3. Overexpression of miR-126 inhibits cell migration and invasion of PTC cells. (A) Cell migration was determined in TPC-1 cells transfected with miR-126 mimic or miR-Ctrl by wound healing assay. (B) Cell invasion was determined in TPC-1 cells transfected with miR-126 mimic or miR-Ctrl by Transwell invasion assay. \* $P < 0.05$ , \*\* $P < 0.01$  vs. miR-Ctrl. PTC, papillary thyroid carcinoma.

downregulated LRP6 expression on mRNA (Fig. 4B) and protein levels (Fig. 4C). To further confirm whether LRP6 is a direct target of miR-126, we constructed pGL3-LRP6 Wt or pGL3-LRP6 Mut plasmid, then transfected pGL3-LRP6 Wt or pGL3-LRP6 Mut plasmid into TPC-1 cells, along with miR-126 mimic or miR-Ctrl for luciferase assay evaluation. Luciferase

assay further revealed that TPC-1 cells transfected with miR-126 mimic repressed wild-type LRP6-3'UTR reporter activity ( $P < 0.01$ ), while miR-126 mimic had no inhibition effect on the mutant LRP6-3'UTR reporter activity (Fig. 4D), indicating the direct regulation of miR-126 in the 3'UTR of LRP6 mRNA.




Figure 4. miR-126 targets the LRP6 gene in PTC cells. (A) The predicted miR-126 binding sites in 3'-UTR of LRP6 by TargetScan6.2 and miRanda. (B) qRT-PCR determined LRP6 mRNA expression in TPC-1 cells after transfected with miR-126 mimic or miR-Ctrl. GAPDH was used as an internal control. (C) Western blotting was used to detect LRP6 protein expression in TPC-1 cells after transfected with miR-126 mimic or miR-Ctrl.  $\beta$ -actin was the internal control. (D) Relative luciferase activity was analyzed upon co-transfection with wild-type or mutant-type LRP6 reporter plasmids and miR-126 or miR-Ctrl in TPC-1 cells. \* $P < 0.05$ , \*\* $P < 0.01$  vs. miR-Ctrl. LRP6, lipoprotein receptor-related protein 6; PTC, papillary thyroid carcinoma.




Figure 5. miR-126 suppresses  $\beta$ -catenin signaling pathway activity in TPC-1 cells. (A) Luciferase assay of TCF/LEF transcriptional activity in TPC-1 cells transfected with miR-126 mimic or miR-Ctrl. \* $P < 0.05$ , \*\* $P < 0.01$  vs. miR-Ctrl. (B) Western blotting determined cyclin D1, MMP-7, CCND1 and c-Myc expression in TPC-1 cells after transfected with miR-126 mimic or miR-Ctrl.  $\beta$ -actin was the internal control. TCF, T cell factor.

*Upregulation of miR-126 deactivates Wnt/ $\beta$ -catenin signaling.* It has been shown that LRP6 is closely correlated with Wnt/ $\beta$ -catenin signaling activity; therefore, we further examined whether miR-126 was involved in the regulation of Wnt/ $\beta$ -catenin signaling. As shown in Fig. 5A, the  $\beta$ -catenin reporter assay revealed that ectopic miR-126 markedly

decreased the TCF/LEF activities in TPC-1 cells (Fig. 5A). In addition, we also examined the protein expression levels of downstream genes in the Wnt/ $\beta$ -catenin signaling pathway, including cyclin D1, MMP-7, CCND1 and c-Myc. Western blot assay showed that overexpression of miR-126 obviously downregulated the protein expression in TPC-1 cells (Fig. 5B).




Figure 6. miR-126 suppressed tumor growth of TPC-1 xenografts in nude mice. (A) Representative images of tumors in the different treatment groups. (B) Growth curves for tumor volumes in xenografts of nude mice in each treatment group. (C) Tumor weights of tumor tissue in each treatment group. (D) Determination of LRP6 protein expression level of tumor tissue by western blotting.  $\beta$ -actin was used as an internal control. \* $P < 0.05$ , \*\* $P < 0.01$  vs. miR-Ctrl group. LRP6, lipoprotein receptor-related protein 6.

These data suggest that upregulation of miR-126 deactivates Wnt/ $\beta$ -catenin signaling and decreases TCF/LEF transcriptional activity.

*miR-126 suppresses PTC cell tumorigenicity in vivo.* Based on the observed decreases in migratory, invasive and proliferative behavior in TPC-1 cells transfected with miR-126 *in vitro*, we further examined miR-126 biofunction in suppression of HCC cell tumorigenicity *in vivo* by inoculating nude mice with tumor cells. The results showed that overexpression of miR-126 can significantly suppress the tumor growth of TPC-1 xenografts in nude mice (Fig. 6A) and decreases tumor volume (Fig. 6B) and tumor weight (Fig. 6C) compared to miR-Ctrl group, indicating the suppressive function of miR-126 on PTC cell tumorigenicity *in vivo*. Furthermore, we also determined LRP6 expression of tumor tissue. The result of western blotting showed that LRP6 protein expression was downregulated in the xenograft tumors of miR-126 mimic group compared to the xenograft tumors of miR-Ctrl group (Fig. 6D). These data indicated that miR-126 suppressed PTC cell tumorigenicity *in vivo* by targeting LRP6.

## Discussion

Dysregulation of miRNAs frequently occurs in various types of human cancers, and aberrant expression of miRNAs may contribute to initiation, promotion and progression of human cancers by affecting the expression of multiple target genes (18-20). Thus, a comprehensive understanding of the relationship between specific miRNAs and tumor development is crucial for the diagnosis and therapy of tumors. A number of miRNAs were reported to be involved in cell proliferation, migration and invasion of papillary thyroid

carcinoma (PTC) (21,22). For instance, Huang *et al* (23) reported that forced expression of miR-219-5p suppressed PTC cell proliferation and migration and promoted apoptosis by targeting the estrogen receptor (ER) $\alpha$ . Zhu *et al* (24) showed that miR-182 in PTC promotes cell proliferation and invasion through direct suppression of close homolog of LI (CHL1).

Li *et al* (25) found that downregulation of miR-181b expression causes cellular growth inhibition, promoting cellular apoptosis by targeting CYLD. Chou *et al* (26) reported that upregulation of miR-146b significantly promotes cell migration and invasiveness and increases resistance to chemotherapy-induced apoptosis in PTC. Data from the present study provide evidence that the miR-126 expression levels was significantly downregulated in PTC tissue and PTC cell lines, the aberrant expression of miR-126 was correlated with lymph node metastasis, tumor size and TNM stage, and that upregulation of miR-126 in PTC cells inhibited proliferation, colony formation, migration and invasion, induced cell apoptosis and suppressed tumor growth in a nude mouse model.

miRNA-126 (miR-126), located within the 7th intron of EGFL7 which resides on human chromosome 9, plays a crucial role in controlling angiogenesis by binding to several transcripts (27,28). Accumulating evidence shows that miR-126 expression is commonly downregulated in various types of cancer, act as a tumor suppressor and inhibits cancer cell growth, adhesion, migration and invasion through suppressing a range of important gene targets (9-16). Recently, several novel targets of miR-126 have been confirmed, such as SOX2 (10), VEGF-A (13), CXCR4 (16), PI3KR2 (29), Crk (29), I $\kappa$ B $\alpha$  (30), IRS-1 (31) and ADAM9 (32). In addition, lipoprotein receptor-related protein 6 (LRP6) has also been reported to be a target gene of miR-126 in human hepatocellular carcinoma (33). In

the present study, we found that LRP6 was a target gene of miR-126 in human thyroid cancer.

LRP6, a member of the expanding low-density lipoprotein (LDL) receptor family, is found to be expressed in different types of human tissues (34). It is well known that LRP6 is one of the Wnt-co-receptors, which activates the transcription of Wnt/ $\beta$ -catenin target genes through promoting  $\beta$ -catenin translocation into the nucleus (35,36). In addition, LRP6 was reported to be upregulated in various types of human cancer, including lung, colon, breast, liver cancer, and to promote the progression of tumors through regulation of the Wnt/ $\beta$ -catenin signaling pathway (37). Deregulation of the Wnt/ $\beta$ -catenin signaling pathway is common in various types of tumors and activation of this pathway is thought to be an early event in tumorigenesis, and plays essential roles during tumor progression (34). Notably, LRP6 has been found to be regulated by several miRNAs such as miR-202 (38), miR-183 (39), miR-610 (40), miR-30e (41) and miR-577 (42). Consistent with these results, in the present study we found that LRP6 is a target of miR-126 by luciferase assay, and that upregulation of miR-126 decreased the expression of LRP6 on mRNA and protein levels. We also found that ectopic miR-126 markedly decreased the TCF/LEF activities in TPC-1 cells. Our results also showed that inhibition of LRP6 by miR-126 resulted in downregulation of the cyclin D1, MMP-7, CCND1 and c-Myc genes, which are the downstream target genes of the Wnt/ $\beta$ -catenin signaling pathway. These results indicated that the tumor suppressive function of miR-126 may be correlated with modulation of the Wnt/ $\beta$ -catenin signaling pathway through targeting LRP6.

In summary, the present study demonstrated that miR-126 is downregulated in PTC tissue and cell lines, and its expression level was significantly associated with lymph node metastasis, TNM stage and tumor size. Overexpression of miR-126 in PTC cells drastically inhibited cell proliferation, colony formation, migration and invasion, induced cell apoptosis and cell cycle arrest at G1 stage *in vitro*, as well as suppressed tumor growth *in vivo*. Moreover, we identified LRP6 as a crucial target gene of miR-126, and found that miR-126 inhibited LRP6 expression and deactivated Wnt/ $\beta$ -catenin signaling pathway, which contributed to suppress PTC growth. These findings suggested that miR-126 could be a potential target for the treatment of PTC.

## References

- Brown RL, de Souza JA and Cohen EE: Thyroid cancer: Burden of illness and management of disease. *J Cancer* 2: 193-199, 2011.
- Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. *Expert Rev Mol Diagn* 8: 83-95, 2008.
- Lang BH, Wong KP, Wan KY and Lo CY: Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. *Ann Surg Oncol* 19: 1257-1263, 2012.
- Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. *Annu Rev Biochem* 79: 351-379, 2010.
- Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* 466: 835-840, 2010.
- Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
- McManus MT: MicroRNAs and cancer. *Semin Cancer Biol* 13: 253-258, 2003.
- Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. *J Pathol* 223: 102-115, 2011.
- Ebrahimi F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. *Exp Mol Pathol* 96: 98-107, 2014.
- Zhao C, Li Y, Zhang M, Yang Y and Chang L: miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting *Sox2*. *Hum Cell* 28: 91-99, 2015.
- Jiang L, Tao C, He A and He X: Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. *World J Surg Oncol* 12: 383, 2014.
- Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. *Virchows Arch* 465: 463-471, 2014.
- Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, Zhou X and Chen C: Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. *Oncotarget* 5: 11873-11885, 2014.
- Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. *PLoS One* 3: e2557, 2008.
- Yamaguchi T, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Nakayama Y, Mori T, Horiguchi S and Miyaki M: Underexpression of miR-126 and miR-20b in hereditary and nonhereditary colorectal tumors. *Oncology* 87: 58-66, 2014.
- Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. *Mol Cell Biochem* 381: 233-242, 2013.
- Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA and Kebebew E: Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. *Ann Surg Oncol* 18: 3443-3452, 2011.
- Hagan JP and Croce CM: MicroRNAs in carcinogenesis. *Cytogenet Genome Res* 118: 252-259, 2007.
- Osada H and Takahashi T: MicroRNAs in biological processes and carcinogenesis. *Carcinogenesis* 28: 2-12, 2007.
- Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. *Adv Exp Med Biol* 774: 1-20, 2013.
- Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cinà D and Libra M: microRNAs and thyroid cancer: Biological and clinical significance (Review). *Int J Mol Med* 30: 991-999, 2012.
- Wei WJ, Shen CT, Song HJ, Qiu ZL and Luo QY: MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: A systematic review and meta-analysis. *Clin Endocrinol*: Dec 16, 2014 (Epub ahead of print). doi: 10.1111/cen.12696.
- Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, *et al*: miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor  $\alpha$ . *J Clin Endocrinol Metab* 100: E204-E213, 2015.
- Zhu H, Fang J, Zhang J, Zhao Z, Liu L, Wang J, Xi Q and Gu M: miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma. *Biochem Biophys Res Commun* 450: 857-862, 2014.
- Li D, Jian W, Wei C, Song H, Gu Y, Luo Y and Fang L: Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. *Int J Clin Exp Pathol* 7: 7672-7680, 2014.
- Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. *J Clin Endocrinol Metab* 98: E196-E205, 2013.
- Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 regulates angiogenic signaling and vascular integrity. *Dev Cell* 15: 272-284, 2008.
- Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ and Kuo CJ: Attribution of vascular phenotypes of the murine *Egfl7* locus to the microRNA *miR-126*. *Development* 135: 3989-3993, 2008.
- Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, Hou N, Ni L, Wang AY, Song TS, *et al*: miR-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes *PI3KR2* and *Crk*, and the tumor suppressor *PLK2*. *Int J Oncol* 45: 1257-1265, 2014.
- Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, Wei G, Wu W, Wu F and Zhou Y: Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor I $\kappa$ B $\alpha$ . *PLoS One* 7: e2782, 2012.

31. Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR-126 in esophageal squamous cell carcinoma. *Oncol Rep* 32: 1225-1233, 2014.
32. Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. *Br J Cancer* 110: 2945-2954, 2014.
33. Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. *J Transl Med* 12: 259, 2014.
34. Joiner DM, Ke J, Zhong Z, Xu HE and Williams BO: LRP5 and LRP6 in development and disease. *Trends Endocrinol Metab* 24: 31-39, 2013.
35. Peröbner I, Karow M, Jochum M and Neth P: LRP6 mediates Wnt/ $\beta$ -catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells. *Int J Biochem Cell Biol* 44: 1970-1982, 2012.
36. Brown SD, Twells RC, Hey PJ, Cox RD, Levy ER, Soderman AR, Metzker ML, Caskey CT, Todd JA and Hess JF: Isolation and characterization of *LRP6*, a novel member of the low density lipoprotein receptor gene family. *Biochem Biophys Res Commun* 248: 879-888, 1998.
37. Li Y, Lu W, He X, Schwartz AL and Bu G: LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. *Oncogene* 23: 9129-9135, 2004.
38. Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B and Ye Q: miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. *FEBS Lett* 588: 1913-1920, 2014.
39. Wang J, Wang X, Li Z, Liu H and Teng Y: MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. *FEBS J* 281: 1355-1365, 2014.
40. Zeng XC, Liu FQ, Yan R, Yi HM, Zhang T, Wang GY, Li Y and Jiang N: Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/ $\beta$ -catenin signaling in human hepatocellular carcinoma. *Mol Cancer* 13: 261, 2014.
41. Wang J, Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, Ma Z, Dai C, Li X, *et al*: miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. *Cell Death Dis* 4: e845, 2013.
42. Zhang W, Shen C, Li C, Yang G, Liu H, Chen X, Zhu D, Zou H, Zhen Y, Zhang D, *et al*: miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway. *Mol Carcinog*: Mar 12, 2015 (Epub ahead of print).

RETRACTED